{
    "symbol": "SEER",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-02 22:32:08",
    "content": " Total revenue for the fourth quarter of 2022 was $4.6 million, representing an increase of 50% compared to $3.1 million in the fourth quarter of 2021. The increase in fourth quarter revenue was primarily due to increased consumable an SP100 instrument sales related to our Proteograph Product Suite, the completion of service projects and lease revenue related to our SP100 instruments. Product-related revenue for the fourth quarter of 2022 was $3.2 million, including related party revenue of $1.7 million and consisted of sales of SP100 instruments, consumable kits and platform evaluations. The increase in revenue is primarily attributable to increased sales of products related to the Proteograph Product Suite and primarily consisted of sales of the Proteograph SP100 instrument consumable kits and platform evaluations, of which $5.2 million was attributed to related parties. The increase in R&D expense was primarily due to an increase in product development efforts related to the Proteograph Product Suite including $10.3 million in employee compensation costs and other related expenses, including stock-based compensation due to growth in R&D personnel and a $4 million increase in allocated overhead related to the allocation of facility expense associated with the build-out of our facilities to support our R&D efforts."
}